Autologous Anti-CD83 CAR T-cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Autologous Anti-CD83 CAR T Cells; Autologous Anti-CD83 CAR-T Cells

Filter by location:

Buffalo, New York1 trial

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.